ArticleScientific reports2026
Ketoacidosis at childhood type 1 diabetes onset negatively affects residual beta-cell functions during the first year after diagnosis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reducing Diabetic Ketoacidosis in Pediatric Type 1 Diabetes: The Impact of Screening Programs and Early Disease-Modifying Treatment.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates whether pediatric patients presenting with diabetic ketoacidosis (DKA) at the time of type 1 diabetes (T1D) diagnosis experience increased insulin requirements, reduced rates of partial remission, and diminished C-peptide secretion over the first year post-diagnosis, relative to children without DKA. The study included 101 children with newly diagnosed T1D. DKA was classified based on the International Society of Pediatric Diabetes (ISPAD) guidelines, and participants were categorized by DKA occurrence and followed for one year post-diagnosis. HbA1c, insulin requirements, and stimulated C-peptide in a mixed meal tolerance test were assessed within 14 days of diagnosis and 6 and 12 months after diagnosis. Our results showed that DKA at T1D negatively affects residual beta-cell function during the year after diagnosis. The DKA cohort had higher insulin requirements across all study visits; however, the occurrence of partial remission did not differ significantly between study groups. Children with DKA at T1D diagnosis exhibit a significant reduction in stimulated C-peptide by 6 months post-diagnosis (AUC: DKA: 0.54 nmol/L vs. non-DKA: 0.68 nmol/L, p < 0.001; Peak: DKA: 0.66 nmol/L vs. non-DKA: 0.88 nmol/L, p < 0.001), a difference that persists at 12 months compared to non-DKA participants (AUC: DKA: 0.42 nmol/L vs. non-DKA: 0.52 nmol/L, p < 0.003; Peak: DKA: 0.51 nmol/L vs. non-DKA: 0.71 nmol/L, p < 0.001).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.